# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.
Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by ...
Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolizatio...
Axonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston...
Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's ‘314 patent and declined to invalidate the challe...